1Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology [ J]. Kidney Int, 1993, 44 (2) : 411- 422.
4Aragao E, Moura LA, Pacheeo-Silva A. Monitoring antiHLA class Ⅰ IgG antibodies in renal transplant recipients [J]. Transplant Proc, 2004, 36 (4): 836-837.
5Jevnikar AM, Mannon RB. Late kidney allograft loss: what we know about it, and what we can do about it[J]. Clin J Am Soc Nephrol, 2008, 3 (Suppl 2) : S56-S67.
6Morrissey PE, Flynn ML, Lin S. Medication noncompliance and its implications in transplant recipients [ J ]. Drugs, 2007, 67 (10): 1463-1481.
7Oh CK, Jeon KO, Kim H J, et al. Metabolic demand and renal mass supply affecting the early graft function after living donor kidney transplantation [ J ]. Kidney Int, 2005, 67 (2) : 744-749.
8He X, Johnston A. Risk factors for allograft failure in United Kingdom renal transplant recipients treated with cyclosporine A [ J ] . Transplantation, 2005, 79 ( 8 ) : 953 -957.
9Ozdemir BH, Ozdemir FN, Haberal N, et al. Vascular endothelial growth factor expression and cyclosporine toxicity in renal allograft rejection[J]. Am J Transplant, 2005, 5 (4 Pt 1): 766-774.
10Houlihan CA, Akdeniz A, Tsalamandris C, et al. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction[ J]. Diabetes Care, 2002, 25 (6) : 1072-1077.
2Trolliet P,Dijoud F,Cotte L.Crescentic glomerulonephritis and crystals with glomerular capillaries in an AIDS patient treated with foscarvir[].American Journal of Nephrology.1995
3Martin M,Manez R,Linden P.A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients[].Transplantation.1994
4Freltas VR.Activity of 9-(1, 3-dihydroxy-2-propoxy)methyl guaine compared with that of acyclovir against human, monkey and rodent cytomegalovirus[].Antimicrobial Agents and Chemotherapy.1985
5Klintman G,Lonngvist B,Oberg B.Intravenous foscarvir for the treatment of sever cytomegalovirus infection in allograft recipients[].Scandinavian Journal of Infectious Diseases.1985
5Ruggenenti P. Chronic allograft nephropathy.a multiple approach to target nonimmunological factors[J].Contributions to Nephrology,2005.87-94.
6Solez K,Vincenti F,Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S.multicenter kidney transplant trial comparing tarolimus versus cyclosporine:a report of the FK506 Kidney Transplant Study Group[J].Transplantation,1998,(12):1736-1740.
7Morales JM,Andres A,Rengel M. Influence of cyclosporin,tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation[J].Nephrology Dialysis Transplantation,2001,(Suppl 1):121-124.
8Dzabic M,Rahbar A,Yaiw KC. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival[J].Clinical Infectious Diseases,2011,(10):969-976.
9Manfro RC. Management of chronic allograft nephropathy[J].J Bras Nefrol,2011,(04):485-492.
10Luo L,Sun Z,Wu W. Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy[J].BMC Nephrology,2012.
